tirzepatide news today recency 3 Endocrinology Obesity articles page [12] Top Stories in Nephrology 2025

The PD-1/VEGF bispecific showed superior PFS against Keytruda in a head-to-head trial in PD-L1+ patients

These concerns are especially real for patients managing chronic conditions or those seeking sustainable, long-term weight loss rather than rapid changes

Furthermore, Semaglutide has been shown to offer additional benefits beyond diabetes control

Your doctor should assess several factors before approving discontinuation, including your current weight status and trajectory, the presence and control of obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease), your readiness and capacity to implement intensive lifestyle modifications, available support systems and resources, and your history of weight cycling or previous weight loss attempts